<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="637">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05152862</url>
  </required_header>
  <id_info>
    <org_study_id>2021/0053</org_study_id>
    <nct_id>NCT05152862</nct_id>
  </id_info>
  <brief_title>Improve Screening Criteria for Retinopathy of Prematurity in Two French Center</brief_title>
  <acronym>DEREP3</acronym>
  <official_title>Evaluation of the Criteria and Modalities of Screening for Retinopathy of Prematurity in Two French Tertiary NICU : is a Simplification Possible ?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Sud Francilien</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Sud Francilien</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to assess whether a delay of the first examination can be safely&#xD;
      considered in French population. Secondary objectives are to describe retinopathy of&#xD;
      prematurity (ROP) in a population of premature from two French tertiary NICU and to identify&#xD;
      co-morbidities associated with the development of severe ROP.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Retinopathy of prematurity (ROP) is a major cause of blindness and visual impairment in&#xD;
      children worldwide. Despite a stable incidence over the last decades, improvements in&#xD;
      neonatal care and survival of extremely premature lead to an increased screening and follow&#xD;
      up of ROP. Retinal examination is painful and can result in clinical deterioration, it also&#xD;
      generates significant health care costs. In this way, several studies suggest the need to&#xD;
      optimize screening without ignoring severe ROP requiring treatment. Recently, SCREENROP in&#xD;
      Canada and SWEDROP studies in Sweden contributed to a modification of the national screening&#xD;
      guidelines with a reducing upper limit at 30 weeks of gestational age (GA) and a postponing&#xD;
      of the first examination. Because of the population studied, those recommendations cannot be&#xD;
      applicable in other countries.&#xD;
&#xD;
      Recommendations in France are to screen infants &lt; 31 GA or 1250 g, first examination should&#xD;
      be performed at PMA 31 in infants &lt; 27 GA and at 4 weeks postnatal age (PNA) in infants born&#xD;
      at 27 GA or more. Our main hypothesis is that a reduction of the screening criteria by&#xD;
      decreasing the upper limit of the threshold at 30 GA and/or postponing the first examination&#xD;
      is acceptable in a population of premature newborns from two French tertiary NICU. This&#xD;
      simplification of the screening modalities could reduced the number of fundus examinations&#xD;
      performed, while limiting risks for the patient as well as costs. This study could be a pilot&#xD;
      study for a national multicenter trial, with the objective of revising national screening&#xD;
      guidelines.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of infants with type 1 or 2 ROP found at routine screening.</measure>
    <time_frame>Day 0</time_frame>
    <description>Number</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time from first retinal examination to treatment of ROP</measure>
    <time_frame>Day 0</time_frame>
    <description>days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postnatal age / SAC at first by gestational age</measure>
    <time_frame>Day 0</time_frame>
    <description>days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from first retinal examination to diagnostic of severe ROP</measure>
    <time_frame>Day 0</time_frame>
    <description>days</description>
  </secondary_outcome>
  <enrollment type="Anticipated">990</enrollment>
  <condition>Retinopathy of Prematurity</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laser</intervention_name>
    <description>Retinal laser photocoagulation</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Anti VEGF</intervention_name>
    <description>Anti-VEGF intravitreous injection</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Cohort will be selected among all premature born between January 2016 and November 2020 and&#xD;
        hospitalized in Centre Hospitalier Sud Francilien (Corbeil Essonnes 91) and Hopital Robert&#xD;
        Debr√© (Paris 75).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Infant with gestational age &lt; 31 weeks and/or birth weight &lt; 1250 g&#xD;
&#xD;
          -  With at least one retinal examination&#xD;
&#xD;
          -  holders of the parental rights informed and not objecting to the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  infants died before 28 days PNA&#xD;
&#xD;
          -  infants with hydrocephaly.&#xD;
&#xD;
          -  infants with significant congenital malformations or genetic abnormalities.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Pauline LEROUX, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Sud Francilien</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pauline LEROUX, MD</last_name>
    <phone>07 72 33 05 63</phone>
    <email>pauline.leroux03@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Caroline TOURTE</last_name>
    <phone>01 61 69 31 50</phone>
    <email>caroline.tourte@chsf.fr</email>
  </overall_contact_backup>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>November 19, 2021</study_first_submitted>
  <study_first_submitted_qc>December 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2021</study_first_posted>
  <last_update_submitted>December 1, 2021</last_update_submitted>
  <last_update_submitted_qc>December 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>birth weight</keyword>
  <keyword>gestational age</keyword>
  <keyword>premature</keyword>
  <keyword>retina</keyword>
  <keyword>screening</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Retinopathy of Prematurity</mesh_term>
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

